Fidler L.M., Keen K.J., Touma Z., Mittoo S. (2016), "Impact of pulmonary disease on patient-reported outcomes and patient-performed functional testing in systemic lupus erythematosus," Lupus [Impact Factor: 2.118], 25, 1004-1011. DOI: 10.1177/0961203316630818.
Rohekar, S., Chan, J., Tse, S., Haroon, N., Chandran, V., Bessette, L., Mosher, D., Flanagan, C., Keen, K., Adams, K., Mallinson, M., Carter, T.J., Rahman, P., Gladman, D., Inman, R. (2015), “A Brief Review of the 2014 Update on the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis Part II: Specific Management Recommendations,” The Journal of Rheumatology [Impact Factor: 3.173], 42, 665-681. DOI: 10.3899/jrheum.141001.
Rohekar, S., Chan, J., Tse, S., Haroon, N., Chandran, V., Bessette, L., Mosher, D., Flanagan, C., Keen, K., Adams, K., Mallinson, M., Carter, T.J., Rahman, P., Gladman, D., Inman, R. (2015), “A Brief Review of the 2014 Update on the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis Part I: Principles of the Management of Spondyloathritis in Canada,” The Journal of Rheumatology [Impact Factor: 3.173], 42, 654-664. DOI: 10.3899/jrheum.141000.
Dunne, J.V., Bankole, J., Keen, K.J. (2013), “Systematic Review of the Role of Microparticles in Systemic Sclerosis,” Current Rheumatology Reviews [Impact Factor: not available, journal first published in 2006], 9 (4, Thematic Issue: Vascular Damage in Systemic Sclerosis), 279-300. DOI: 10.2174/1573397109666140103001139.
Dunne, J.V., Keen, K.J., van Eeden, S.F. (2013), “Circulating Angiopoietin and Tie-2 levels in Systemic Sclerosis,” Rheumatology International [Impact Factor: 1.627], 33, 475-484. DOI: 10.1007/s00296-012-2378-4.
Saketkoo, L.A., Escorpizo, R., Keen, K.J., Fligelstone, K., Distler, O. on behalf of EUSTAR (2012), “International Classification of Functioning, Disability and Health Core Set construction in systemic sclerosis and other rheumatic diseases: a EUSTAR initiative,” Rheumatology [Impact Factor: 4.435], 51, 2170-2176. DOI:10.1093/rheumatology/kes185.
Dunne, J.V., van Eeden, S.F., Keen, K.J. (2012), “L-selectin and Skin Damage in Systemic Sclerosis,” PLoS ONE [Impact Factor 3.534] 7(9): e44814. DOI: 10.1371/journal.pone.0044814.
Keen, K.J., van Eeden, S.F., Dunne, J.V. (2012), “Limited Cutaneous and Diffuse Cutaneous Scleroderma: Circulating Biomarkers Differentiate Lung Involvement,” Rheumatology: Current Research [Impact Factor: not available as this is a new journal], S1, 7 pp. and 6 supplemental online pages. DOI: 10.4172/2161-1149.S1-006.
Wang, L., Keen, K.J., and Holland, B. (2011), “Estimation of reliability in a three-factor model,” Statistics in Medicine [Impact Factor: 2.037], 30, 1254-1265. DOI: 10.1002/sim.4182.
Gibbs, A.L., Keen, K.J., Wang, L. (2011), “Case studies in data analysis,” The Canadian Journal of Statistics [Impact Factor: 0.699], 39, 181-217.
Fidler L.M., Keen K.J., Touma Z., Mittoo S. (2016), "Impact of pulmonary disease on patient-reported outcomes and patient-performed functional testing in systemic lupus erythematosus," Lupus [Impact Factor: 2.118], 25, 1004-1011. DOI: 10.1177/0961203316630818.